In small ac­qui­si­tion, Ab­b­Vie adds Lan­dos and its IBD drug to post-Hu­mi­ra plans

Ab­b­Vie is ac­quir­ing au­toim­mune start­up Lan­dos Bio­phar­ma, ac­cord­ing to a Mon­day an­nounce­ment, aim­ing to cap­i­tal­ize on an IBD drug that re­cent­ly en­tered Phase 2. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER